OOIR: Observatory of International Research

Papers

(The median citation count of Cancer and Metastasis Reviews is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities	351
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	213
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms	202
Obesity and cancer	140
Clonal tracking in cancer and metastasis	132
Regulation of dormancy during tumor dissemination: the role of the ECM	113
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression	103
The functions and modifications of tRNA-derived small RNAs in cancer biology	91
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions	84
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer	68
Targeting lipid metabolism in cancer: neuroblastoma	67
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?	67
CAR T-cell therapy to treat multiple myeloma: current state and future directions	61
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?	59
p73 isoforms meet evolution of metastasis	58
Cell-cell interactions mediating primary and metastatic breast cancer dormancy	55
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review	53
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond	47
Biography—Mathieu Boissan, Pharm.D., Ph.D	45
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives	45
Preface	42
Neuropeptide Y in cancer—biological functions and potential clinical implications	40
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	40
Biographies	38
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance	38

The multifaceted mechanisms of malignant glioblastoma progression and clinical implications	36
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance	36
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy	35
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy	35
The role of cancer cell bioenergetics in dormancy and drug resistance	35
Clusterin: a marker and mediator of chemoresistance in colorectal cancer	35
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis	35
Short-chain fatty acids in cancer pathogenesis	35
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development	34
Tumor necrosis factor superfamily signaling: life and death in cancer	34
Vaping and tumor metastasis: current insights and progress	33
Carcinoma of unknown primary (CUP): an update for histopathologists	33
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions	33
Clinical interventions to break the obesity and cancer link: a narrative review	33
Functional and clinical roles of stromal PDGF receptors in tumor biology	30
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy	30
Kenneth V. Honn, Ph.D. (1946–2023)	29
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution	29
The emerging roles of histone demethylases in cancers	29
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy	28
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape	28
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective	27
OX40/OX40 ligand and its role in precision immune oncology	27
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies	26
Ferroptosis: iron release mechanisms in the bioenergetic process	25
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect	25
HOXA9 transcription factor is a double-edged sword: from development to cancer progression	24
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases	24
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting	24
Biographies	23
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics	23
Is cancer an intelligent species?	23
New progress of tuberculosis scar carcinoma	23
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs	23
The diversity of natural killer cell functional and phenotypic states in cancer	22
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets	22
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases	22
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer	22
Metastasis suppressor genes and their role in the tumor microenvironment	22
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment	22
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets	22
Metastasis suppressor genes in clinical practice: are they druggable?	22
The role of bone marrow adipocytes in cancer progression: the impact of obesity	21
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis	21
Lost at SCLC: a review of potential platinum sensitizers	21
De- “bug”-ing the microbiome in lung cancer	20
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy	20
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma	20
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer	20
Biography—Mikhail Kolonin	19

The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers	19
Preface	19
Preface	19
Role of myeloid-derived suppressor cells in tumor recurrence	19
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions	18
The role of obesity and bariatric surgery-induced weight loss in breast cancer	18
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer	18
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?	18
Biographies	17
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment	17
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors	17
Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine	17
Potential biomarkers for immunotherapy in non-small-cell lung cancer	17
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance	17
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics	17
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings	16
Epigenetic drugs in cancer therapy	16
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies	16
Epigenetic control of pancreatic cancer metastasis	16
The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin	16
The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response	15
Natural compounds targeting nuclear receptors for effective cancer therapy	15
Minimally invasive biomarkers for triaging lung nodules—challenges and future perspectives	15
The timing of adiposity and changes in the life course on the risk of cancer	15
Correction to: Connecting the human microbiome and pancreatic cancer	15
Insights into the role of senescence in tumor dormancy: mechanisms and applications	15
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance	15
Preface	14
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases	14
Recapitulating the potential contribution of protein S-palmitoylation in cancer	14
Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies	14
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance	14
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance	14
Advancements in gene therapies targeting mutant KRAS in cancers	14
Oral delivery of RNAi for cancer therapy	14
Evolving strategies for addressing CAR T-cell toxicities	13
Epigenetic markers and therapeutic targets for metastasis	13
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response	13